Cemsidomide

DRUG4 trials

Sponsors

C4 Therapeutics Inc., C4 Therapeutics, Inc.

Conditions

Lymphoma, Non-Hodgkin'sMultiple MyelomaMultiple Myeloma (MM)Relapsed/Refractory Multiple Myelomarelapsed/refractory multiple myeloma

Phase 1

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

Active, not recruitingNCT04756726

C4 Therapeutics, Inc.Lymphoma, Non-Hodgkin's, Multiple Myeloma

Start: 2021-04-27End: 2026-12-31Target: 224Updated: 2026-03-25

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

RecruitingNCT07280013

C4 Therapeutics, Inc.Multiple Myeloma (MM)

Start: 2026-02-06End: 2029-06-01Target: 60Updated: 2026-08-12

Phase 2

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

RecruitingNCT07284758

C4 Therapeutics, Inc.Multiple Myeloma, Relapsed/Refractory Multiple Myeloma

Start: 2026-02-18End: 2030-03-01Target: 100Updated: 2026-08-06

A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)

Not yet recruitingCTIS2025-524181-26-00

C4 Therapeutics Inc.relapsed/refractory multiple myeloma

Target: 33Updated: 2026-05-26

Related Papers

MOMENTUM: A phase 2, open-label, single-arm, multicenter study to evaluate the efficacy of cemsidomide + dexamethasone in subjects with relapsed/refractory multiple myeloma (RRMM).

Journal of Clinical Oncology2026-05-28

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma

Blood2024-11-055 citations

Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, in Patients with Non-Hodgkin's Lymphoma

Blood2024-11-054 citations

Abstract P39: CFT7455, a novel IKZF1/3 degrader enhances the anti-myeloma activity of monoclonal and bispecific antibodies by augmenting immune responses

Blood Cancer Discovery2024-03-045 citations

Abstract CT186: Pharmacokinetic (PK) profile of a novel IKZF1/3 degrader, CFT7455, enables significant potency advantage over other IKZF1/3 degraders in models of multiple myeloma (MM) and the results of the initial treatment cohort from a first-in-human (FIH) phase 1/2 study of CFT7455 in MM

Cancer Research2022-06-1511 citations

A Phase 1 Study of CFT7455, a Novel Degrader of IKZF1/3, in Multiple Myeloma and Non-Hodgkin Lymphoma

Blood2021-11-0521 citations